{"id":"0-1-bromfenac","_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=0.1% bromfenac","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T07:20:57.605215+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T07:21:03.886646+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=0.1% bromfenac","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T07:21:04.181230+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1077/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T07:21:05.197870+00:00"}},"_dailymed":null,"_scrapedAt":"2026-03-27T23:41:38.267Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T07:21:07.671251+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT07178639","phase":"NA","title":"Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract Surgery","status":"RECRUITING","sponsor":"Nemocnice Kolín","startDate":"2025-08-01","conditions":"Macular Oedema, Cataract Surgery, NSAID (Non-Steroidal Anti-Inflammatory Drug)","enrollment":150},{"nctId":"NCT03317847","phase":"PHASE4","title":"Bromfenac Versus Dexamethasone After Cataract Surgery","status":"COMPLETED","sponsor":"Azienda USL Reggio Emilia - IRCCS","startDate":"2017-10-16","conditions":"Inflammation Eye","enrollment":92},{"nctId":"NCT02137161","phase":"PHASE4","title":"Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery","status":"COMPLETED","sponsor":"Azienda USL Reggio Emilia - IRCCS","startDate":"2013-11","conditions":"Cataract, Pseudoexfoliation Syndrome","enrollment":62},{"nctId":"NCT06785090","phase":"PHASE4","title":"Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery","status":"COMPLETED","sponsor":"Inas Abd","startDate":"2023-05-01","conditions":"Cataract, Cystoid Macular Edema After Phacoemulsification","enrollment":87},{"nctId":"NCT05158699","phase":"PHASE3","title":"Effectiveness of Periocular Drug Injection in CATaract Surgery","status":"TERMINATED","sponsor":"Luigi Rondas","startDate":"2021-10-13","conditions":"Macular Edema, Cystoid Macular Edema, Retinal Disease","enrollment":628},{"nctId":"NCT05715385","phase":"PHASE4","title":"Comparison of Treatments in Diabetic Macular Edema","status":"COMPLETED","sponsor":"Babasaheb Ambedkar Memorial Hospital","startDate":"2014-11","conditions":"Diabetic Macular Edema","enrollment":60},{"nctId":"NCT04940338","phase":"PHASE4","title":"PCME Prevention in Patients With NPDR","status":"COMPLETED","sponsor":"Klinički Bolnički Centar Zagreb","startDate":"2021-05-01","conditions":"Cystoid Macular Edema Following Cataract Surgery","enrollment":90},{"nctId":"NCT01310127","phase":"PHASE4","title":"Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%","status":"COMPLETED","sponsor":"Toyos Clinic","startDate":"2010-11","conditions":"Inflammation, Pseudophakia","enrollment":23},{"nctId":"NCT04022811","phase":"PHASE4","title":"Effect of Bromfenac on Pain Related to Pterygium Surgery","status":"COMPLETED","sponsor":"Zhongshan Ophthalmic Center, Sun Yat-sen University","startDate":"2016-10","conditions":"Pterygium, Pain","enrollment":60},{"nctId":"NCT01657266","phase":"PHASE2","title":"Efficacy and Safety of PRO-155 Versus Nevanac in Post Phacoemulsification","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2013-12","conditions":"Cataract, Phacoemulsification Cataract Surgery","enrollment":160},{"nctId":"NCT03597867","phase":"PHASE3","title":"PGE2 Levels in Patient Treated With NSAIDs","status":"COMPLETED","sponsor":"University of Trieste","startDate":"2018-04-25","conditions":"Ocular Inflammation","enrollment":104},{"nctId":"NCT01774474","phase":"PHASE3","title":"PRevention of Macular EDema After Cataract Surgery","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2013-07-10","conditions":"Cystoid Macular Edema, Cataract, Diabetes Mellitus","enrollment":1127},{"nctId":"NCT01475877","phase":"","title":"Bromday Versus Nevanac Eye Drops to Control Pain Following Photorefractive Keratectomy","status":"COMPLETED","sponsor":"Virdi Eye Clinic","startDate":"2011-05","conditions":"Myopia","enrollment":20},{"nctId":"NCT02681679","phase":"NA","title":"Topical 0.1% Bromfenac Sodium and Prostaglandin E2 Inhibition in Cataract Surgery","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2014-10","conditions":"Cataract","enrollment":60},{"nctId":"NCT02361645","phase":"PHASE3","title":"NSAIDs and PGE2 Levels in Vitrectomy Patients","status":"COMPLETED","sponsor":"Università degli Studi di Brescia","startDate":"2014-03","conditions":"Vitreous Inflammation","enrollment":70},{"nctId":"NCT00198445","phase":"PHASE3","title":"Safety and Efficacy Study of Topical Bromfenac Versus Placebo to Treat Ocular Inflammation After Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2003-05","conditions":"Postoperative Complications, Cataract","enrollment":527},{"nctId":"NCT01001806","phase":"PHASE4","title":"A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification","status":"COMPLETED","sponsor":"Frank A. Bucci, Jr., M.D.","startDate":"2009-10","conditions":"Cataracts","enrollment":126},{"nctId":"NCT00828477","phase":"PHASE4","title":"Evaluation of Comfort With Xibrom (Bromfenac Ophthalmic Solution)0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT)","status":"COMPLETED","sponsor":"Bp Consulting, Inc","startDate":"2009-01","conditions":"Intraocular Pressure","enrollment":25},{"nctId":"NCT00595543","phase":"PHASE4","title":"Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5%","status":"COMPLETED","sponsor":"Bp Consulting, Inc","startDate":"2008-01","conditions":"Acute Pseudophakic Cystoid Macular Edema","enrollment":166},{"nctId":"NCT00377546","phase":"PHASE4","title":"Comparison of Vitreous Levels of Acular LS 0.04%, Xibrom 0.09%, and Nevanac 0.1%","status":"COMPLETED","sponsor":"Innovative Medical","startDate":"","conditions":"Vitrectomy","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL1077"},"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["0.5%Tobramycin dexamethasone","0.3% sodium hyaluronate"],"phase":"marketed","status":"active","brandName":"0.1% bromfenac","genericName":"0.1% bromfenac","companyName":"Zhongshan Ophthalmic Center, Sun Yat-sen University","companyId":"zhongshan-ophthalmic-center-sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T07:21:07.671251+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}